David J Brooks MD DSc FRCP(UK) FMedSci (UK) FEAN is Professor of Neurology and PET Clinical Science,  Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, and also Visiting Professor of Neurology in the Department of Medicine, Imperial College London and part-time Professor of Neurology at Dept of Nuclear Medicine, Aarhus University, Denmark. He is on the Grant Awards Board of Alzheimer Research UK and the Weston Brain Institute. He was Chairman of the European Research Council Neuroscience Panel  (Advanced Grants) and a reviewer for JPND 2020. He was also previously on the Biomedical Research Advisory Panel of Alzheimer UK  and on the Scientific Advisory Boards of Parkinson’s UK, and the German Dementia and Parkinson Kompetenz Networks.

He was  a member of the NMRC International Expert Panel Singapore and was Chairman of the NUHS Scientific Advisory Panel. He was a member of the Scientific Advisory Board of the Michael J. Fox Foundation for Parkinson's Disease Research (2002-2006), UK Medical Research Council Neuroscience and Mental Health Board (2004-2007), Wellcome Trust Neuroscience Panel (2001-2003) and was Chairman of the Scientific Issues Committee of the Movement Disorder Society (1998-2002).

David is UK Editor of Current Neuropharmacology. He was an Associate Editor of Brain and Molecular Imaging and Biology. He is on the Editorial Boards of Journal of Parkinson’s Disease, Synapse, and NPJ Parkinson's Disease. He was on the Editorial Boards of Annals of Neurology, Movement Disorders, and Parkinsonism and Related Disorders. In 2001 he was elected a Fellow of the Academy of Medical Science, UK and a Fellow of the American Neurology Association. In 2018 he was elected a Fellow of the European Academy of Neurology. His research involves the use of positron emission tomography and magnetic resonance imaging to diagnose and study the progression of Alzheimer’s and Parkinson’s disease and his work is on the highly cited list with an h index of 123. He has been a recipient of  a Danish Alzheimer Foundation Prize, the Kuhl-Lassen award  (Society of Nuclear Medicine), and was invited to give the Ramon Y Cajal Lecture (Spanish Academy of Medicine), the Stahn Fahn Lecture (International Movement Disorder Society) and Cotzias Lecture (Spanish Neurology Society) Lectures. He is a consultant for GE Healthcare, Biogen, and previously Plexxikon, and GenePod.

Area of expertise: Neuroimaging, Parkinson's and Alzheimer's diseases

Google Scholar: Click here.

Selected reports:

1.      Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann. Neurol. 1990; 28: 547-555

2.      Koepp MJ, … Brooks DJ, … Grasby PM. Evidence for striatal dopamine release during a video game. Nature 1998; 393: 266-268.

3.      Cagnin A, Brooks DJ, et al. In vivo measurement of microglial  activation  in dementia. Lancet  2001;  358: 461-467.

4.      Gill SS, … Brooks DJ, … Heywood  P. Direct brain infusion of glial cell line-derived neu rotrophic  factor  (GDNF)  in  Parkinson's  Disease.  Nature Medicine 2003; 9: 589-595.

5.      Rinne JO, Brooks DJ, et al. [11C]PiB PET supports reduced cortical fibrillar Ag  in Alzheimer's disease patients  treated  with  bapineuzumab. Lancet Neurol 2010;  9:  363-372.

6.      Piccini P, Brooks DJ, Bjorkl und A, Gunn RN, Grasby PM, Rimoldi 0, Brundi n P, Hagell P, Rehncrona S, Widner H, Lindvall O. Dopamine release from nigral tra nsplants visualised in vivo in a Parkinson's patient. Nature Neuroscience 1999;  2:  1137-1140. 

7.    Rascol O, Brooks DJ, Korczyn AD, De Deyn P, Clarke C, Lang AE. Dyskinesia in Parkinson's Disease: A 5-Year Study of ropinirole versus levodopa. New Eng.J Med. 2000; 342: 1484-1491.

• Hansen AK, Knudsen K, Lillethorup TP, Landau AM, Parbo P, Fedorova T, Audrain H, Bender D, Ostergaard K, Brooks DJ, Borghammer P. In vivo imaging of neuromelanin in Parkinson's disease using ¹⁸F-AV-1451 PET. Brain 2016, 139, 2039-2049.
• Firbank MJ, Yarnall AJ, Lawson RA, Duncan GW, Khoo TK, Petrides GS, O'Brien JT, Barker RA, Maxwell RJ, Brooks DJ, Burn DJ. Cerebral glucose metabolism and cognition in newly diagnosed Parkinson’s disease: ICICLE-PD study. Journal of Neurology, Neurosurgery, and Psychiatry 2017, 88(4), 310-316.
• Duncan GW, Firbank MJ, Yarnall AJ, Khoo TK, Brooks DJ, Barker RA, Burn DJ, O'Brien JT. Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease?. Movement Disorders 2016, 31(1), 103-110.
• Breen DP, Nombela C, Vuono R, Jones PS, Fisher K, Burn DJ, Brooks DJ, Reddy AB, Rowe JB, Barker RA. Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. Movement Disorders 2016, 31(7), 1062-1066.
• Brooks DJ, Tambasco N. Imaging Synucleinopathies. Movement Disorders 2016, 31(6), 814-829.
• Borghammer P, Knudsen K, Brooks DJ. Imaging Systemic Dysfunction in Parkinson's Disease. Current Neurology and Neuroscience Reports 2016, 16(6), 51.
• Brooks DJ. Molecular imaging of dopamine transporters. Ageing Research Reviews 2016, 30, 114-121.
• Peraza LR, Lawson RA, Firbank JM, Yarnall A, Duncan GW, Khoo TK, Brooks D, O'Brien JT, Barker RA, Burn D, Taylor JP. Principal component discriminant analysis of mild cognitive impairment in Parkinson’s disease reveals early functional changes in the resting state. In: Neuroinformatics 2016 INCF Conference. 2016, Reading, UK: Frontiers Media S.A.
• Yarnall AJ, Lawson RA, Duncan GW, Breen DP, Khoo TK, Brooks D, Barker RA, Taylor JP, Burn DJ. Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson's Disease?. Journal of Parkinson's Disease 2015, 5(4), 743-743.
• Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yarnall AJ, Duncan GW, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn DJ, O'Brien JT. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 2015, 138, 2974-2986.
• Mak E, Su L, Williams G, Lawson R, Yarnall A, Gordon D, Adrian O, Tien K, Brooks D, Rowe J, Barker R, Burn D, O'Brien J. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. In: 17th IPA International. 2015, Berlin, Germany: Cambridge University Press.
• Nombela C, Rowe JB, Winder-Rhodes SE, Hampshire A, Owen AM, Breen DP, Duncan GW, Khoo TK, Yarnall AJ, Firbank MJ, Chinnery PF, Robbins TW, O'Brien JT, Brooks DJ, Burn DJ, Barker RA, ICICLE-PD Study Grp. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 2014, 137, 2743-2758.
• Stokholm MG, Iranzo A, Ostergaard K, Serradell M, Otto M, Svendsen KB, Garrido A, Vilas D, Borghammer P, Santamaria J, Moller A, Gaig C, Brooks DJ, Tolosa E, Pavese N. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A case-control study. The Lancet Neurology 2017, 16(10), 789-796.
• Parbo P, Ismail R, Hansen K, Mårup F, Gottrup H, Braendgaard H, Eriksson B, Eskildsen S, Lund T, Tietze A, Edison P, Pavese N, Stokholm M, Borghammer P, Hinz R, Aanerud J, Brooks DJ. Brain inflammation accompanies amyloid in a majority of mild cognitive impairment cases due to Alzheimer’s disease. Brain 2017, 140(7), 2002-2011.
• Sommerauer M, Fedorova TD, Hansen AK, Knudsen K, Otto M, Jeppesen J, Frederiksen Y, Blicher JU, Geday J, Nahimi A, Damholdt MF, Brooks DJ, Borghammer P. Evaluation of the noradrenergic system in Parkinson’s disease: an ¹¹C-MeNER PET and neuromelanin MRI study. Brain 2018, 141(2), 496-504.
• Hansen AK, Damholdt MF, Fedorova TD, Knudsen K, Parbo P, Ismail R, Ostergaard K, Brooks DJ, Borghammer P. In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography. Movement Disorders 2017, 32(6), 922-927.
• Peraza LR, Nesbitt D, Lawson RA, Duncan GW, Yarnall AJ, Khoo TK, Kaiser M, Firbank MJ, O'Brien JT, Barker RA, Brooks DJ, Burn DJ, Taylor JP. Intra- and inter-network functional alterations in Parkinson's disease with mild cognitive impairment. Human Brain Mapping 2017, 38(3), 1702-1715.
• Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yarnall AJ, Duncan GW, Mollenhauer B, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn DJ, O'Brien JT. Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. Neurobiology of Aging 2017, 55, 78-90.
• Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders 2017, 32(9), 1264-1310.
• Dani M, Brooks DJ, Edison P. Suspected non Alzheimer's pathology – Is it non-Alzheimer's or non-amyloid?. Ageing Research Reviews 2017, 36, 20-31.
• Politis M, Sauerbier A, Loane C, Pavese N, Martin A, Corcoran B, Brooks DJ, Ray-Chaudhuri K, Piccini P. Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. Movement Disorders 2017, 32(2), 235-240.
• Buckley CJ, Sherwin PF, Smith APL, Wolber J, Weick SM, Brooks DJ. Validation of an electronic image reader training programme for interpretation of [¹⁸F]flutemetamol β-amyloid PET brain images. Nuclear Medicine Communications 2017, 38(3), 234-241.
• Pagano G, Molloy S, Bain PG, Rabiner EA, Chaudhuri KR, Brooks DJ, Pavese N. Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease. Neurology 2016, 87(23), 2451-2456.
• Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O'Brien JT, Brooks DJ, Barker RA, Burn DJ. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013, 80(3), 276-281.
• Yarnall AJ, Khoo TK, Duncan GW, Barker RA, Brooks DJ, Burn DJ. Anti-cholinergic load: Is there a cognitive cost in early Parkinson’s disease?. In: The Movement Disorders Society 16th International Congress of Parkinson’s Disease and Movement Disorders. 2012, Dublin, Ireland.
• Khoo TK, Duncan GW, Yarnall AJ, Brooks DJ, Barker RA, O'Brien JT, Burn DJ. Apathy in incident Parkinson’s disease. In: The Movement Disorders Society 16th International Congress of Parkinson’s Disease and Movement Disorders. 2012, Dublin, Ireland.
• Yarnall AJ, Rochester L, David R, Duncan GW, Khoo TK, Barker RA, Brooks DJ, Baker MR, Burn DJ. Cholinergic dysfunction in Parkinson’s disease with mild cognitive impairment: a short latency afferent inhibition study. In: The Movement Disorders Society 16th International Congress of Parkinson’s Disease and Movement Disorders. 2012, Dublin, Ireland.
• Duncan GW, Khoo TK, Yarnall AJ, O'Brien JT, Brooks DJ, Barker RA, Burn DJ. Elevated homocysteine levels and cognitive dysfunction in an incident cohort of non-demented Parkinson’s disease patients. In: The Movement Disorders Society 16th International Congress of Parkinson’s Disease and Movement Disorders. 2012, Dublin, Ireland.
• Brooks DJ. PET and SPECT imaging in progressive supranuclear palsy. In: MOVEMENT DISORDERS. 2004.
• Bhatia K, Brooks DJ, Burn DJ, Clarke CE, Grosset DG, MacMahon DG, Playfer J, Schapira AHV, Stewart D, Widliams AC, Parkinsons Dis Consensus Working G. Updated guidelines for the management of Parkinson's disease. Hospital Medicine 2001, 62(8), 456-470.
• Bhatia K, Brooks DJ, Burn DJ, Clarke CE, Playfer J, Sawle GV, Schapira AHV, Stewart D, Williams AC, Parkinson Dis Consensus Working Grp. Guidelines for the management of Parkinson's disease. HOSPITAL MEDICINE 1998, 59(6), 469-480.
• Sommerauer M, Hansen AK, Parbo P, Fedorova TD, Knudsen K, Frederiksen Y, Nahimi A, Brooks DJ, Borghammer P. Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients. Movement Disorders 2018, 33(6), 1006-1010.
• Stokholm MG, Iranzo A, Østergaard K, Serradell M, Otto M, Svendsen KB, Garrido A, Vilas D, Parbo P, Borghammer P, Santamaria J, Møller A, Gaig C, Brooks DJ, Tolosa E, Pavese N. Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. Neurobiology of Disease 2018, 115, 9-16.
• Knudsen K, Fedorova TD, Hansen AK, Sommerauer M, Otto M, Svendsen KB, Nahimi A, Stokholm MG, Pavese N, Beier CP, Brooks DJ, Borghammer P. In vivo staging of pathology in REM Sleep Behaviour Disorder – a multi-modality imaging case-control study. Lancet Neurology 2018, 17(7), 618-628.
• Minett T, Su L, Mak E, Williams G, Firbank M, Lawson RA, Yarnall AJ, Duncan GW, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn D, O'Brien JT. Longitudinal diffusion tensor imaging changes in early Parkinson’s disease: ICICLE-PD study. Journal of Neurology 2018, 265(7), 1528-1539.
• Lillethorup TP, Glud AN, Alstrup AKO, Mikkelsen TW, Nielsen EH, Zaer H, Doudet DJ, Brooks DJ, Sørensen JCH, Orlowski D, Landau AM. Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs. Experimental Neurology 2018, 303, 142-152.
• Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chételat G, Oliveira CRD, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere K, de Leon MJ, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Doorn LJCVW, Waldemar G, Wallin AK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia 2018, 14(7), 913-924.
• Pasquini J, Ceravolo R, Qamhawi Z, Lee JY, Deuschl G, Brooks DJ, Bonuccelli U, Pavese N. Progression of tremor in early stages of Parkinson’s disease: a clinical and neuroimaging study . Brain 2018, 141(3), 811-821.
• Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Hoglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, Lewitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J. Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology 2018, 90(2), 74-82.
• Edison P, Brooks DJ. Role of neuroinflammation in Alzheimer’s trajectory and in vivo quantification using PET. Journal of Alzheimer's Disease 2018, 64(s1), S339-S351.
• Hansen AK, Brooks DJ, Borghammer P. MAO-B Inhibitors Do Not Block In Vivo Flortaucipir ([¹⁸F]-AV-1451) Binding. Molecular Imaging and Biology 2018, 20(3), 356-360.
• Jeppesen J, Otto M, Frederiksen Y, Hansen AK, Fedorova TD, Knudsen K, Nahimi A, Brooks DJ, Borghammer P, Sommerauer M. Observations on REM sleep without atonia assessed with a semi-automated scoring algorithm. Clinical Neurophysiology 2018, 129(3), 541-547.
• McGinnity CJ, Riaño Barros DA, Trigg W, Brooks DJ, Hinz R, Duncan J, Koepp MJ, Hammers A. Simplifying [¹⁸F]GE-179 PET: are both arterial blood sampling and 90-minute acquisitions essential?. EJNMMI Research 2018, 8, 46.
• McGinnity CJ, Arstad E, Beck K, Brooks DJ, Coles JP, Duncan JS, Galovic M, Hinz R, Hirani E, Howes OD, Jones PA, Koepp MJ, Luo F, Riano Barros DA, Singh N, Trigg W, Hammers A. Comment on "In Vivo [¹⁸F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primates". ACS Chemical Neuroscience 2019, 10(1), 768-772.
• Parbo P, Ismail R, Sommerauer M, Stokholm MG, Hansen AK, Hansen KV, Amidi A, Schaldemose JL, Gottrup H, Braendgaard H, Eskildsen SF, Borghammer P, Hinz R, Aanerud J, Brooks DJ. Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. Neurobiology of Disease 2018, 117, 211-216.
• Lillethorup TP, Glud AN, Landeck N, Alstrup AKO, Jakobsen S, Vang K, Doudet DJ, Brooks DJ, Kirik D, Hinz R, Sorensen JC, Landau AM. In vivo quantification of glial activation in minipigs overexpressing human α-synuclein. Synapse 2018, 72(12), e22060.
• Dani M, Wood M, Mizoguchi R, Fan Z, Walker Z, Morgan R, Hinz R, Biju M, Kuruvilla T, Brooks DJ, Edison P. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer’s disease. Brain 2018, 141(9), 2740-2754.
• McGinnity CJ, Riano Barros DA, Trigg W, Brooks DJ, Hinz R, Duncan JS, Koepp MJ, Hammers A. Simplifying [¹⁸F]GE-179 PET: are both arterial blood sampling and 90-min acquisitions essential?. EJNMMI Research 2018, 8, 46.
• Ismail R, Hansen AK, Parbo P, Brændgaard H, Gottrup H, Brooks DJ, Borghammer P. The Effect of 40-Hz Light Therapy on Amyloid Load in Patients with Prodromal and Clinical Alzheimer’s Disease. International Journal of Alzheimer's Disease 2018, 2018, 6852303.
• Schubert JJ, Veronese M, Marchitelli L, Bodini B, Tonietto M, Stankoff B, Brooks DJ, Bertoldo A, Edison P, Turkheimer FE. Dynamic ¹¹C-PiB PET shows cerebrospinal fluid flow alterations in Alzheimer’s disease and multiple sclerosis. Journal of Nuclear Medicine 2019, 60(10), 1452-1460.
• Ismail R, Parbo P, Hansen KV, Schaldemose JL, Dalby JB, Tietze A, Kjeldsen PL, LaCour SH, Qvist P, Gottrup H, Eskildsen SF, Brooks DJ. Abnormal Amyloid Load in Mild Cognitive Impairment: The Effect of Reducing the PiB‐PET Threshold. Journal of Neuroimaging 2019, 29(4), 499-505.
• Metaxas A, Thygesen C, Kempf SJ, Anzalone M, Vaitheeswaran R, Petersen S, Landau AM, Audrain H, Teeling J, Darvesh S, Brooks DJ, Larsen MR, Finsen B. Ageing and amyloidosis underlie the molecular and pathological alterations of tau in a mouse model of familial Alzheimer’s disease. Scientific Reports 2019, 9, 15758.
• Andersen K, Hansen AK, Sommerauer M, Fedorova TD, Knudsen K, Vang K, VanDenBerge N, Kinnerup M, Nahimi A, Pavese N, Brooks DJ, Borghammer P. Altered sensorimotor cortex noradrenergic function in idiopathic REM sleep behaviour disorder – a PET study. Parkinsonism & Related Disorders 2020, 75, 63-69.
• Møller A, Thomsen KR, Brooks DJ, Mouridsen K, Blicher J, Hansen KV, Lou HC. Attenuation of dopamine-induced GABA release in problem gamblers. Brain and Behavior 2019, 9(3), e01239.
• Pasquini J, Durcan R, Wiblin L, Stokholm MG, Lynn Rochester L, Brooks DJ, Burn D, Pavese N. Clinical implications of early caudate dysfunction in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry 2019, 90(10), 1098-1104.
• Sridharan S, Raffel J, Nandoskar A, Record C, Brooks DJ, Owen D, Sharp D, Muraro PA, Gunn R, Nicholas R. Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [¹⁸F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter. Molecular Imaging and Biology 2019, Epub ahead of print.
• Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, Lawrence R, McFarlane B, Tadros G, Ridha BH, Bannister C, Walker Z, Archer H, Coulthard E, Underwood BR, Prasanna A, Koranteng P, Karim S, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Harrison J, Brooks DJ, Passmore AP, Ballard C, Edison P. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: Study protocol for a randomised controlled trial (ELAD study). Trials 2019, 20(1), 191.
• Femminella GD, Dani M, Wood M, Fan Z, Calsolaro V, Atkinson R, Hinz R, Brooks DJ, Edison P. Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. Neurology 2019, 92(12), e1331-e1343.
• Chetelat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, VandeGiessen E, Agosta F, Barkhof F, Brooks DJ, Carrillo MC, Dubois B, Fjell A, Frisoni GB, Hansson O, Herholz K, Hutton BF, JackJr CR, Lammertsma AA, Landau SM, Minoshima S, Nobili F, Nordberg A, Ossenkoppele R, Oyen WJ, Perani D, Rabinovici GD, Scheltens P, Villemagne VL, Zetterberg H, Drzezga A. Molecular neuroimaging in dementia clinical diagnosis and research: where are we headed?. Lancet Neurology 2019. Submitted.
• Durcan R, Wiblin L, Lawson RA, Khoo TK, Yarnall AJ, Duncan GW, Brooks DJ, Pavese N, Burn DJ. Prevalence and duration of non‐motor symptoms in prodromal Parkinson's disease. European Journal of Neurology 2019, 26(7), 979-985.
• Pasquini J, Ceravolo R, Brooks DJ, Bonuccelli U, Pavese N. Progressive loss of raphe nuclei serotonin transporter in early Parkinson’s disease: a longitudinal ¹²³I-FP-CIT SPECT study. Parkinsonism & Related Disorders 2019, 77, 170-175.
• Dani M, Wood M, Mizoguchi R, Fan Z, Edginton T, Hinz R, Win Z, Brooks DJ, Edison P. Tau Aggregation Correlates with Amyloid Deposition in Both Mild Cognitive Impairment and Alzheimer's Disease Subjects. Journal of Alzheimer's Disease 2019, 70(2), 453-463.
• Kubler D, Wachter T, Cabanel N, Su Z, Turkheimer FE, Dodel R, Brooks DJ, Oertel WH, Gerhard A. Widespread microglial activation in multiple system atrophy. Movement Disorders 2019, 34(4), 564-568.
• Møller A, RømerThomsen K, Brooks DJ, Mouridsen K, Blicher J, Hansen KV, Lou HC. Attenuation of dopamine-induced GABA release in problem gamblers Short running title: L-dopa effect on GABA release in gamblers. Brain and Behaviour 2018. Submitted.
• Helmich RC, Vaillancourt DE, Brooks DJ. The future of brain imaging in Parkinson’s disease. Journal of Parkinson's Disease 2018, 8(s1), S47-S51.
• Vibholm AK, Landau AM, Alstrup AKO, Jacobsen J, Vang K, Munk OL, Dietz MJ, Orlowski D, Sørensen JCH, Brooks DJ. Activation of NMDA Receptor Ion Channels by Deep Brain Simulation in the Pig Visualised with[¹⁸F]GE-179 PET. Brain Stimulation 2020, 13(4), 1071-1078.
• Horsager J, Andersen KB, Knudsen K, Skjærbæk C, Fedorova TD, Okkels N, Schaeffer E, Bonkat SK, Geday J, Otto M, Sommerauer M, Danielsen EH, Bech E, Kraft J, Munk OL, Hansen SD, Pavese N, Göder R, Brooks DJ, Berg D, Borghammer P. Brain-first vs. Body-first Parkinson’s disease: a multi-modal imaging case-control study. Brain 2020, 143(10), 3077-3088.
• Gersel Stokholm M, Iranzo A, Ostergaard K, Serradell M, Otto M, Bacher Svendsen K, Garrido A, Vilas D, Fedorova TD, Santamaria J, Moller A, Gaig C, Hiraoka K, Brooks DJ, Okamura N, Borghammer P, Tolosa E, Pavese N. Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder. European Journal of Neurology 2020, 27(4), 644-652.
• Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, Brooks DJ, Darcourt J, Dickson JC, Douglas D, Drzezga A, Dubroff J, Ekmekcioglu O, Garibotto V, Herscovitch P, Kuo P, Lammertsma A, Pappata S, Penuelas I, Seibyl J, Semah F, Tossici-Bolt L, Van de Giessen E, Van Laere K, Varrone A, Wanner M, Zubal G, Law I. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European Journal of Nuclear Medicine and Molecular Imaging 2020, epub ahead of print.
• Binda KH, Lillethorup PT, Real CC, Simone BL, Brooks DJ, Chacur M, Landau AM. Exercise restores synaptic density in a rodent model of Parkinson’s disease. Neuroimage 2020. Submitted.
• Stokholm MG, Garrido A, Tolosa E, Serradell M, Iranzo A, Østergaard K, Borghammer P, Møller A, Parbo P, Stær K, Brooks DJ, Martí MJ, Pavese N. Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers. Journal of Neurology 2020, 267, 2296-2300.
• Nielsen RB, Parbo P, Ismail R, Dalby R, Tietze A, Brændgaard H, Gottrup H, Brooks DJ, Østergaard L, Eskildsen SF. Impaired Perfusion And Capillary Dysfunction In Prodromal Alzhemer’s Disease. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2020, 12(1), e12032.
• Thomsen MB, Jacobsen J, Lillethorup TP, Schacht AC, Simonsen M, Romero-Ramos M, Brooks DJ, Landau AM. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET. Journal of Cerebral Blood Flow and Metabolism 2021, 41(4), 819-830.
• Parbo P, Madsen LS, Ismail R, Zetterberg H, Blennow K, Eskildsen SF, Jensen TV, Brooks DJ. Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer’s disease. Alzheimer's Research and Therapy 2020, 12, 3.
• Thomsen MB, Schacht MC, Alstrup AKO, Lillethorup TP, Baerentzen SL, Noer O, Brooks DJ, Landau AM. Preclinical PET Studies of [¹¹C]UCB-J Binding in Minipig Brain. Molecular Imaging and Biology 2020, 22, 1290-1300.
• Hansen AK, Parbo P, Ismail R, Østergaard K, Brooks DJ, Borghammer P. Tau Tangles in Parkinson’s Disease: A 2-Year Follow-Up Flortaucipir PET Study. Journal of Parkinson's Disease 2020, 10(1), 161-171.
• Ismail R, Parbo P, Madsen LS, Hansen AK, Hansen KV, Schaldemose JL, Kjeldsen PL, Stokholm MG, Gottrup H, Eskildsen SF, Brooks DJ. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study. Journal of Neuroinflammation 2020, 17, 151.
• Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ, Nombela C, Winder-Rhodes S, Evans JR, Rowe JB, Mollenhauer B, Kruse N, Hudson G, Chinnery PF, O'Brien JT, Robbins TW, Wesnes K, Brooks DJ, Barker RA, Burn DJ, ICICLE-PD Study Group. Characterizing mild cognitive impairment in incident Parkinson disease The ICICLE-PD Study. Neurology 2014, 82(4), 308-316.
• Femminella GD, Livingston NR, Raza S, van der Doef T, Frangou E, Love S, Busza G, Calsolaro V, Carver S, Holmes C, Ritchie CW, Lawrence RM, McFarlane B, Tadros G, Ridha BH, Bannister C, Walker Z, Archer H, Coulthard E, Underwood B, Prasanna A, Koranteng P, Karim S, Junaid K, McGuinness B, Passmore AP, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Tan T, Holscher C, Harrison J, Brooks DJ, Ballard C, Edison P. Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects?. Alzheimer's Research and Therapy 2021, 13, 47.
• Brooks DJ. Imaging Familial and Sporadic Neurodegenerative Disorders associated with Parkinsonism. Neurotherapeutics 2021, Epub ahead of print.
• Kinnerup MB, Sommerauer M, Damholdt FM, Schaldemose JL, Ismail R, Terkelsen AJ, Stær K, Hansen A, Fedorova TD, Knudsen K, Skjærbæk C, Borghammer P, Pavese N, Brooks DJ, Nahimi A. Preserved noradrenergic function in Parkinson´s disease patients with rest tremor. Neurobiology of Disease 2021, 152, 105295.
• Andersen KB, Hansen AK, Damholdt MF, Horsager J, Skjærbæk C, Gottrup H, Klit H, Danielsen EH, Brooks DJ, Borghammer P. Reduced synaptic density in patients with Lewy body dementia: an [11C]UCB-J PET imaging study. Movement Disorders 2021. In Press.
• Chetelat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, van de Giessen E, Agosta F, Barkhof F, Brooks DJ, Carrillo MC, Dubois B, Fjell AM, Frisoni GB, Hansson O, Herholz K, Hutton BF, Jack CR, Lammertsma AA, Landau SM, Minoshima S, Nobili F, Nordberg A, Ossenkoppele R, Oyen WJG, Perani D, Rabinovici GD, Scheltens P, Villemagne VL, Zetterberg H, Drzezga A. Amyloid-PET and ¹⁸F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. The Lancet Neurology 2020, 19(11), 951-962.
• Mullin S, Stokholm MG, Hughes D, Mehta A, Parbo P, Hinz R, Pavese N, Brooks DJ, Schapira AHV. Brain microglial activation increased in glucocerebrosidase (GBA1) mutation carriers. Movement Disorders 2021, 36(3), 774-779.
• Horsager J, Andersen KB, Knudsen K, Skjaerbaek C, Fedorova TD, Okkels N, Schaeffer E, Bonkat SK, Geday J, Otto M, Sommerauer M, Danielsen EH, Bech E, Kraft J, Munk OL, Hansen SD, Pavese N, Goder R, Brooks DJ, Berg D, Borghammer P. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. Brain 2020, 143(10), 3077-3088.
• Staer K, Iranzo A, Stokholm MG, Ostergaard K, Serradell M, Otto M, Svendsen KB, Garrido A, Vilas D, Santamaria J, Moller A, Gaig C, Brooks DJ, Borghammer P, Tolosa E, Pavese N. Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder. Parkinsonism and Related Disorders 2020, 81, 89-93.
• Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, Lawrence R, McFarlane B, Tadros G, Ridha BH, Bannister C, Walker Z, Archer H, Coulthard E, Underwood BR, Prasanna A, Koranteng P, Karim S, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Harrison J, Holscher C, Brooks DJ, Passmore AP, Ballard C, Edison P. Erratum: Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study) (Trials (2019) 20 1 (191)). Trials 2020, 21(1), 660.
• Brooks DJ. Future imaging in dementia. Seminars in Nuclear Medicine 2021, 51(3), 303-308.
• Eskildsen SF, Iranzo A, Stokholm MG, Stær K, Østergaard K, Serradell M, Otto M, Svendsen KB, Garrido A, Vilas D, Borghammer P, Santamaria J, Møller A, Gaig C, Brooks DJ, Tolosa E, Østergaard L, Pavese N. Impaired cerebral microcirculation in isolated rapid eye movement sleep behaviour disorder. Brain 2021, (ePub ahead of Print).
• Vibholm AK, Landau AM, Møller A, Jacobsen J, Vang K, Munk OL, Orlowski D, Sørensen JCH, Brooks DJ. NMDA receptor ion channel activation detected in vivo with [¹⁸F]GE-179 PET after electrical stimulation of rat hippocampus. Journal of Cerebral Blood Flow and Metabolism 2021, 41(6), 1301-1312.
• Thomsena MB, Ferreira SA, Schachta AC, Jacobsena J, Simonsena M, Betzerb C, Jensen PH, Brooks DJ, Landau AM, Romero-Ramos M. PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats. Neurobiology of Disease 2021, 149, 105229.
• Xu Z, Anderson KN, Saffari SE, Lawson RA, Chaudhuri KR, Brooks David, Pavese N. Progression of sleep disturbances in Parkinson’s Disease. A 5-year longitudinal study. Journal of Neurology 2021, 268, 312-320.
• Binda KH, Lillethorup TP, Real CC, Bærentzen SL, Nielsen MN, Orlowski D, Brooks DJ, Chacur M, Landau AM. ­­Exercise protects synaptic density in a rat model of Parkinson’s disease. Experimental Neurology 2021, 342, 113741.
• Pagano G, Molloy S, Bain PG, Rabiner EA, Chaudhuri KR, Brooks DJ, Pavere N. Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: a [¹¹C]-PHNO PET study. Parkinsonism & Related Disorders 2021, (ePub ahead of Print).
• Doppler CEJ, Kinnerup MB, Brune C, Farrher E, Betts M, Fedorova TD, Schaldemose JL, Knudsen K, Ismail R, Seger AD, Hansen AK, Stær K, Fink GR, Brooks DJ, Nahimi A, Borghammer P, Sommerauer M. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson’s disease. Brain 2021, Epub ahead of print.
• Pasquini J, Brooks DJ, Pavese N. The cholinergic brain in Parkinson’s disease. Movement Disorders Clinical Practice 2021, epub ahead of print.